Latest News
- Psoriasis
Thursday, June 15, 2017 | Phase 3/4 Trials, PracticalDermatology.com
PsA Patients Failing Anti-TNF Drugs May Do Well on Taltz
New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant o…
Read the full story
Wednesday, June 07, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Sun Pharmaceutical Industries Ltd
Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studies
Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who rece…
Read the full story
Tuesday, June 06, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates
FDA Clears Clarify Medical Core Technology for At-home UVB Phototherapy
The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic ski…
Read the full story
Tuesday, June 06, 2017 | PracticalDermatology.com, PracticalDermatology.com, Research and Publications
Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasis
A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers a…
Read the full story
Wednesday, May 24, 2017 | PracticalDermatology.com, Product Launches and Updates, Sun Pharmaceutical Industries Ltd
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumab
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the tre…
Read the full storyWednesday, May 24, 2017 | PracticalDermatology.com, Research and Publications, 23andMe , Psoriasis
Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clues
A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how -- and why -- psoriasis develops. University of Michigan researchers, wor…
Read the full story
Tuesday, May 23, 2017 | PracticalDermatology.com, PracticalDermatology.com, Research and Publications, Psoriasis
Tweaking TWEAK May Cool Inflammation in Pso and AD
New research pinpoints a common driver of skin inflammation in both psoriasis and atopic dermatitis. The findings, published in the May 22, 2017 issue of Nature Communications, showed that TWE…
Read the full storyWednesday, May 17, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Valeant NJ
Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launch
Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stac…
Read the full story
Thursday, May 04, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Atopic Dermatitis , Eczema, Leo
LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairs
Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs str…
Read the full storyThursday, May 04, 2017 | Personnel/Company News, PracticalDermatology.com, Pfizer
Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis
(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ® …
Read the full storyThursday, April 27, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com
ASA Honors Researchers At Annual Meeting of the Society for Investigative Dermatology
Richard Edelson, MD Chair and Professor, Department of Dermatology, Yale School of Medicine, took home the David Martin Carter Mentor Award from the American Skin Association at the Annual M…
Read the full storyFriday, April 21, 2017 | PracticalDermatology.com, Product Launches and Updates, Valeant NJ
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasis
Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per mon…
Read the full storyWednesday, April 19, 2017 | PracticalDermatology.com, PracticalDermatology.com, Research and Publications, Atopic Derm, Atopic Dermatitis , Eczema
Topical Cannabinoids May Soothe Itchy Skin
Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, accordin…
Read the full story
Thursday, March 30, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates, AbbVie
FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Information
The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis…
Read the full storyFriday, March 24, 2017 | PracticalDermatology.com, Research and Publications
Study: Severe Psoriasis More Common in Men
Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly …
Read the full story
